Skip to content

A Pilot, Open-Label Study on the Effect of PureMune with Beta-Glucan on the Improvement of Immunity in Healthy Individuals During the Flu Season

A Pilot, Open-Label Study on the Effect of PureMune with Beta-Glucan on the Improvement of Immunity in Healthy Individuals During the Flu Season

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000040893
Enrollment
Unknown
Registered
2020-12-14
Start date
2020-12-09
Completion date
Unknown
Last updated
2021-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immunity

Interventions

experimental group:Intake PureMune Beta-Glucan

Sponsors

ImmuDyne Nutritional LLC
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. 18 to 80 years of age at enrollment, inclusive; 2. Female or Male subjects between 18 and 80 years old; 3. Agree not to take any nutritional medications or supplements during the study; 4. Agree not to participate in other interventional nutrition study for the duration of this study; 5. Fully understand the nature, purpose, benefits and potential risks and side effects of this study; 6. Agree to sign the informed consent form and is willing to participate in the study and comply with the study design.

Exclusion criteria

Exclusion criteria: 1. Subject has disease of cardiovascular, cerebrovascular, liver, kidney, hematopoietic system and other diseases; 2. Subject is pregnant or lactating, or has an allergy to beta-glucan; 3. Subject currently takes any drugs or food supplement related to the study product in recent days, which interferes with the study product; 4. Subject currently takes drugs, nutrition supplements or on any therapy for the treatment of improving immunity and not willing to discontinue them; 5. Subject participated another clinical trial in the past three months; 6. Subject is not willing to comply the study procedures; 7. Subject has any diseases that can affect the evaluation of the study product; 8. Subject takes any drugs that can affect the evaluation of the study product.

Design outcomes

Primary

MeasureTime frame
IFN-?;IL-2;TNF-a/ß;IL-4;IL-5;IL-6;IL-10;IL-12;IL-13;IL-17;IgE;CD44;PBMCs;

Countries

China

Contacts

Public ContactDingfu Zhong
1772143482@qq.com+86 15905892382

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026